mastering-input.blogspot.com
The Department of Health’s proposed regulations relatedc to marketing activities by pharmaceutical and medical device manufacturerz will create an unquestionably restrictive environment forthese companies. However, the administratiobn wisely opted to exclude from the requirementa disclosure of legitimate payments related toclinicalo trials. A vocal minority has since raisedfa stink, suggesting that the state health officialsw caved to industry. This is The administration has simply done theright thing. Recent data from showed that in biopharmaceutical-related companies were responsible foralmosyt 55,000 jobs in the state.
The university’d also projected that 15,000 new jobs in the biopharmaceutical industry will be generatesd in Massachusettsby 2014. Lawmakers showesd great determination and vision in championintg the recently enacted lifesciences initiative. These effortes could have been jeopardized if not for the actionsd of the Departmentof Health. Our statew officials took crucial steps to ensurd that ongoing clinical researchn conducted in partnership between local physicians and academic medical centers and life sciences companiesz is not threatened by overly restrictivedisclosure requirements.
It is the rightg decision for thepublic health, for this uniques and dynamic life sciences sector, and for the near-ter m prospects of our loca l economy. Kelly Thompson Clark Presidentand CEO,
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment